Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raquel de Paz

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Blood|April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myelomaCatarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.
Blood Cancer Journal|February 10, 2021
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practiceValentín Garcia-Gutiérrez, Alejandro Luna, Juan M Alonso-Dominguez, et al.
Haematologica|March 21, 2019
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenanceJosé A García-Marco, Javier López Jiménez, Valle Recasens, et al.
Cytotherapy|October 28, 2023
Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)Cristina Ferreras, Clara Hernández-Blanco, Alejandro Martín-Quirós, et al.
American Journal of Hematology|July 26, 2014
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?Valentin García-Gutiérrez, Jose Manuel Puerta, Begoña Maestro, et al.
Cancers|February 25, 2023
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase InhibitorsLucía Pérez-Lamas, Alejandro Luna, Concepción Boque, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Blood|April 17, 2020
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myelomaCatarina Maia, Noemi Puig, Maria-Teresa Cedena, et al.
Blood Cancer Journal|February 10, 2021
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practiceValentín Garcia-Gutiérrez, Alejandro Luna, Juan M Alonso-Dominguez, et al.
Haematologica|March 21, 2019
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenanceJosé A García-Marco, Javier López Jiménez, Valle Recasens, et al.
Cytotherapy|October 28, 2023
Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)Cristina Ferreras, Clara Hernández-Blanco, Alejandro Martín-Quirós, et al.
American Journal of Hematology|July 26, 2014
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?Valentin García-Gutiérrez, Jose Manuel Puerta, Begoña Maestro, et al.
Cancers|February 25, 2023
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase InhibitorsLucía Pérez-Lamas, Alejandro Luna, Concepción Boque, et al.
Pageof 7